Page 3 - Multiple Myeloma Program News Today

The FDA granted an accelerated approval for Talvey to treat patients with relapsed/refractory multiple myeloma.

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...

Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

New Blood Cancer Therapy Gives a New Lease on Life To 73% of Patients - Industry Tap

Predicting when new drugs come to market in the United States has never been an exact science, but several drugs that could be approved in 2023 could have a significant impact on health for millions of people.

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

MONDAY, Dec. 12, 2022 (HealthDay News) -- An experimental immunotherapy appears highly effective in attacking bone marrow cancer, with nearly three in four patients responding to the treatment, new clinical

An antibody infusion could be a game changer for people with persistent multiple myeloma, an aggressive blood cancer. The therapy was successful about 73 per cent of the time.

Get latest articles and stories on Health at LatestLY. The treatment, which is referred to as a "bispecific antibody," binds to both T cells and multiple myeloma cells and instructs the T cells, which are white blood cells that can be used to fight off diseases Health News | Experimental Cancer Therapy Shows 73 Pc Success Rate in Trials: Study.

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...